JAB Therapeutics Regains Global Rights to SHP2 Inhibitor JAB-3312 from AbbVie

Zhitong Finance APP reported that Jacobio-B (01167) announced that AbbVie issued a termination notice for the license and cooperation agreement (the Agreement) based on portfolio and strategic decision-making reasons. The Agreement involves the global development and commercialization of SHP2 inhibitors licensed by Jacobio to AbbVie under the Agreement. After the termination of the Agreement, Jacobio will regain the global rights to these SHP2 inhibitors previously granted to AbbVie, including decision-making rights for all development, commercialization, production, and regulatory activities related to SHP2 inhibitors worldwide. Jacobio will also have the right to pre-sell these SHP2 inhibitors globally. Both parties will cooperate to orderly transfer responsibilities under the Agreement within 180 days. During the transition period, AbbVie will continue to reimburse all expenses under the pre-approved development plan.

SHP2 Inhibitor Plays a Key Role in Avoiding Drug Resistance When Combined with Various Oncogenic Driver Inhibitors. Jacobio’s Promising SHP2 Inhibitor (JAB-3312) Is Currently Undergoing Global Phase IIa Trials. Jacobio Remains Committed to Advancing Its Global Clinical Development Programs, Including Targeted Therapies Combining KRAS G12C Inhibitors and Various Tumor Driver Inhibitors. Clinical Data on the Combination of JAB-3312 and Glecirasib (Jacobio’s KRAS G12C Inhibitor) Are Expected to Be Released in the Second Half of 2023. The Company Continues to Be Confident and Dedicated to Accelerating the Global Development of Its SHP2 Inhibitor.

Jacobio is a clinical-stage biotechnology company focused on developing novel drugs for undruggable targets in cancer. Its robust pipeline includes eight clinical assets in clinical stages and multiple assets in the clinical trial (IND)-enabling stage.